Abstrait
Le traitement du cancer du rein métastatique (CRM) a été transformé par ľavènement des antiangiogéniques: sunitinib (Sutent®) et sorafénib (Nexavar®), en attendant que le temsirolimus (Torisel®) et le bévacizumab (Avastin®) obtiennent à leur tour leur autorisation de mise sur le marché (AMM). Ce chapitre traite uniquement des deux premiers antiangiogéniques, qui ont obtenu ľAMM en 2006 dans le traitement du CRM.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Références
Houk BE, Bello CL, Michaelson MD et al. (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 5027
Amato RJ, Harris P, Dalton M et al. (2007) A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 5026
Bukowski R, Cella D, Gondek K et al. (2007) Effects of sorafenib on symptoms and quality-of-life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30: 220–7
Robert C, Soria JC, Spatz A et al. (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6: 491–500
Motzer RJ, Hutson TE, Tomczak P et al. (2007) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. N Engl J Med 356: 115–124
Escudier B, Eisen T, Stadler WM et al. (2007) Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs): A Randomized, Double-Blind Placebo-Controlled Phase III Trial of Sorafenib, an Oral Multi-Kinase Inhibitor in Advanced Renal Cell Carcinoma. N Engl J Med 356: 125–34
Robert C, Faivre S, Raymond E et al. (2005) Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143: 313–4
Calabrese C, Fabbri A, Areni A et al. (2007) Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol 22: 809–14
Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7: 193–201
Izzedine H, Rixe O, Billemont B et al. (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50: 203–18
Force T, Krause DS, Van Etten RA. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332–44
Faivre S, Delbaldo C, Vera K et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25–35
Rini BI, Tamaskar I, Shaheen P et al. (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81–3
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Escudier, B., Robert, C. (2008). Comment gérer au mieux la toxicité des traitements antiangiogéniques?. In: Le Cancer du rein. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-71651-5_14
Download citation
DOI: https://doi.org/10.1007/978-2-287-71651-5_14
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-71650-8
Online ISBN: 978-2-287-71651-5